<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142839</url>
  </required_header>
  <id_info>
    <org_study_id>12</org_study_id>
    <nct_id>NCT05142839</nct_id>
  </id_info>
  <brief_title>Palliation of Gastric Outflow Obstruction in Case of Concomitant Biliary Obstruction.</brief_title>
  <acronym>B-GOOD</acronym>
  <official_title>Palliation of Gastric Outflow Obstruction in Case of Concomitant Biliary Obstruction. A Retrospective, Multicenter Study. (B-GOOD Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EUS-guided drainages has been largely widespread during the last 10 years, even thanks to the&#xD;
      advent of dedicated devices, such as lumen apposing metal stents (LAMSs).&#xD;
&#xD;
      Above all, EUS-guided choledochoduodenostomy (EUS-CD) is to date considered a valuable option&#xD;
      of treatment in case of distal malignant biliary obstruction in case of failure of endoscopic&#xD;
      retrograde cholangiopancreatography (ERCP) due to the presence of a gastric or duodenal&#xD;
      obstruction, unreachable papilla in case of altered anatomy, infiltrated papilla or failure&#xD;
      of deep cannulation of the common bile duct. This modality of drainage demonstrated&#xD;
      satisfying results, with high rate both of technical and clinical success with acceptable&#xD;
      rate of adverse events.&#xD;
&#xD;
      When the distal malignant biliary obstruction is associated to signs and symptoms of gastric&#xD;
      outflow obstruction (GOO) due to the presence of a gastric or duodenal stenosis, a&#xD;
      concomitant or subsequent palliation of the stenosis may be required.&#xD;
&#xD;
      Recently, EUS-guided gastroenterostomy (EUS-GEA) has been introduced for the palliation of&#xD;
      GOO, showing good results although technically challenging.&#xD;
&#xD;
      To date, endoscopic treatment in case of GOO, enteral stenting and EUS-GEA are possible&#xD;
      alternatives. However, available data demonstrated that EUS-GEA seems to be superior to&#xD;
      enteral stenting in terms of rate of reinterventions during long-term follow-up, especially&#xD;
      when life expectancy is superior to 6 months.&#xD;
&#xD;
      However, data are lacking regarding which is the best strategy when GOO is associated to&#xD;
      distal malignant biliary obstruction, especially when EUS-CD is performed. This is an hot&#xD;
      topic, as it has been supposed that EUS-CD has higher rate of adverse events, especially food&#xD;
      impaction, when a duodenal stenosis is present.&#xD;
&#xD;
      The aim of our study, therefore, is to perform a retrospective multicenter study collecting&#xD;
      all consecutive patients affect by distal malignant biliary obstruction drained using EUS-CD,&#xD;
      with associated GOO treated with concomitant or subsequent duodenal stenting or EUS-GEA, in&#xD;
      order to evaluate clinical efficacy, long term outcomes and severity of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success for EUS-CD</measure>
    <time_frame>6 Months</time_frame>
    <description>Decreased of total bilirubin &gt; 50% or normalization of bilirubin within 2 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical success for EUS-GEA and enteral stenting</measure>
    <time_frame>6 Months</time_frame>
    <description>resolution of symptoms of GOO, with improvement in enteral diet assumption (creamy or solid) comparing to the baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Malignant Biliary Obstruction</condition>
  <arm_group>
    <arm_group_label>EUS-CD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUS-guided choledochoduodenostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-GEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUS-guided gastroenterostomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-CD</intervention_name>
    <description>EUS-guided choledochoduodenostomy</description>
    <arm_group_label>EUS-CD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-GEA</intervention_name>
    <description>EUS-guided gastroenterostomy</description>
    <arm_group_label>EUS-GEA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - patients undergoing affected by distal malignant biliari obstruction and gastric outflow&#xD;
        obstruction undergone EUS-CD and EUS-GEA or enteral stenting drainage between January 2016&#xD;
        to September 2021&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Enteral stenting or EUS-GEA performed before EUS-CD&#xD;
&#xD;
          -  Provide an estimate of number of records you plan to review and time period that it&#xD;
             will be covered.January 2016 to September 2021&#xD;
&#xD;
          -  If the number of records you plan to exceeds 500, please provide the following:&#xD;
&#xD;
        N/A&#xD;
&#xD;
        - Provide an estimate of how long it will take you to complete the study, including the&#xD;
        time for data analysis.&#xD;
&#xD;
        3 month for data collection and 3 weeks for data analysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Anderloni, MD</last_name>
    <phone>0039-02-82247308</phone>
    <email>andrea.anderloni@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Fugazza, MD</last_name>
    <phone>0039-02-82247021</phone>
    <email>alessandro.fugazza@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastroenterology, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyloric Stenosis</mesh_term>
    <mesh_term>Gastric Outlet Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

